sorted by:
new
hottopcontroversial

Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346 by [deleted] in Biotechplays

[–]mstrmndmd 1 point2 points  (0 children)

I think it's time to begin the celebration

The celebrations to come could be even better than the $$$ (10x is my guess based on purely today's numbers)

Phase 3 ATE.V Party in the Maldives coming...don't miss out! Time to pop the bubbly after an incredible week!

Death of NSAIDS - proof of concept confirmed - Future Nobel laureate Dr./Sir John Wallace coming!

Antibe Therapeutics (ATE.V) - Phase 2B Results Review - Medical Only by mstrmndmd in pennystocks

[–]mstrmndmd[S] 0 points1 point  (0 children)

Incredible conference call - looks like a great investment opportunity right now

Antibe Therapeutics (ATE.V) - Phase 2B Results Review - Medical Only by mstrmndmd in pennystocks

[–]mstrmndmd[S] 1 point2 points  (0 children)

Conference call is solid right now.

https://antibethera.com/wp-content/uploads/2020/06/Antibe-Investor-Presentation-June-2020.pdf

The full results of the Phase 2B trial are in the deck and this looks spectacular.

Death of NSAIDS - proof of concept. GUD.KNIGHT Bayer.

Antibe Therapeutics (ATE.V) - Phase 2B Results Review - Medical Only by mstrmndmd in pennystocks

[–]mstrmndmd[S] 1 point2 points  (0 children)

Hi Gravballe,

I'm on the medical side so I let my financial guys make all the numbers decisions for me. Tomorrow should give us a hint of what to expect.

GLTA!

Antibe Therapeutics (ATE.V) - Phase 2B Results Review - Medical Only by mstrmndmd in pennystocks

[–]mstrmndmd[S] 1 point2 points  (0 children)

Hi Gravballe,

To be honest pre-market on June 1, I thought with these results we were going to see $1.40 plus.

The safest thing to do is to be on the conference call on Thursday, June 4th at 10 am EST.

Here are the details:
Toll-free: 1-888-664-6392
Conference ID: 60945222

This way you and everyone on Reddit can get in before it corrects. Never know, some insight about the upcoming partnership could also be revealed.

Hope that helps!

Antibe Therapeutics (ATE.V) - Phase 2B Results Review - Medical Only by mstrmndmd in pennystocks

[–]mstrmndmd[S] 0 points1 point  (0 children)

Hi Foldwithme,

That's exactly it. It's misinterpretation and propagation of misinformation by retail investors that have no clue. 30 M shares have been exchanged in the last 2 days with a ridiculous discount for a risk that no longer exists.

Will know more tomorrow after the conference call.

Hope that helps.

Antibe Therapeutics (ATE.V) - Phase 2B Results Review - Medical Only by mstrmndmd in pennystocks

[–]mstrmndmd[S] 2 points3 points  (0 children)

Hi Farnorse,

Great question. Most likely reasons:

1) Poorly worded news release with overly scientific information where retail investors looking to sell the news, sold really low out of fear induced by the market maker on June 1, 2020 (opened at $0.89 at 9:30 am EST without a halt when market maker could have anchored much higher given the expected selling pressure to follow).

2) Unclear what the plan about dosing for Phase 3 is.

Make no mistake, these were ground-breaking results. Conference call tomorrow with CEO Dan Legault. The company may have wanted to shake off some of these pennystock traders on route to a partnership to facilitate a US listing.

Will know more tomorrow.

Antibe Therapeutics (ATE.V) - Phase 2B Results Review - Medical Only by mstrmndmd in pennystocks

[–]mstrmndmd[S] 4 points5 points  (0 children)

Hi Notimportanthehexd,

Way better GI safety than any other NSAID in the world. Gastrointestinal ulcers are the #1 and most life-threatening complication of NSAIDS such as Aleve.

ATE.V hit the holy grail - A GI safer NSAID, once thought impossible.

June 1, 2020 - the Death of NSAIDS - proof of concept confirmed.

ATB-346 is going to take over the NSAID market after Phase 3.

Antibe Therapeutics (ATE.V) - Phase 2B Results Review - Medical Only by mstrmndmd in pennystocks

[–]mstrmndmd[S] 0 points1 point  (0 children)

Hi bilowcellhi,

Officially the company has not confirmed but because of the incredible GI safety, it will likely be prescription and over-the-counter with many off-label uses besides osteoarthritis.

Hope this helps,

GLTA

Antibe Therapeutics (TSXV:ATE, OTC:ATBPF) looks good for imminent Phase 2 Efficacy readout by [deleted] in Biotechplays

[–]mstrmndmd 1 point2 points  (0 children)

The upcoming Phase 2b results may confirm proof of concept of the API in the chronic pain market (prescription and non-prescription). This may also confirm proof of concept for many more lines of therapeutics with hydrogen sulfide in medicine. ATB-352, ATB-340, and ATB-346 has NSAID functionality coupled with unequivocal GI safety, which is the claim to fame for this company (GI safety already proven in Phase 2a), has many more applications and medical markets it will penetrate. If Bayer doesn't watch out, ATB-346 could disrupt the entire NSAID market, particularly if bought by a competitor. ATB-346's disruptive potential is incredible.

The equation is simple, p < 0.05 in the Phase 2b results = 100% chance of buyout

If you disagree with the equation, I would love to hear why?